Latest research

New research has provided evidence that infection with the Epstein Barr virus acts as a trigger for people to develop MS.

The MS Trust is delighted that Ponvory (ponesimod) has been approved in England and Wales for people with active relapsing remitting multiple sclerosis.

If you are not eligible to receive Covid-19 treatment automatically on the basis of increased risk, you may be able to get antiviral medication through the PANORAMIC clinical trial.

People with MS can get effective treatments if they get Covid-19. This article explains more about molnupiravir (Lagevrio) and sotrovimab (Xetrudy) and how to get them if you catch coronavirus.

NICE has rejected Fampyra (fampridine) as an NHS treatment for people with MS-related walking problems in the draft of the updated multiple sclerosis clinical guideline.

The MS Trust is delighted that Ponvory (ponesimod) has been approved in Scotland for people with active relapsing remitting multiple sclerosis.

Results from an early stage clinical trial suggests that temelimab may promote remyelination and prevent loss of nerve cells.

The MS Trust is very disappointed that NICE does not recommend ponesimod (Ponvory) as an NHS treatment in England and Wales.

We interview Dr Sharmilee Gnanapavan, a Consultant Neurologist at Bart's Health to get some answers on what's new in the world of disease modifying drugs and multiple sclerosis.

Fewer than 13% of people in England eligible for Sativex can access it, according to a new report published today. People living in Wales, Scotland and Northern Ireland also face difficulties.

This study took an in-depth look at the dating experiences of a small group of people living with MS.

The MS Trust is delighted that Kesimpta (ofatumumab) has been approved by SMC for people with active relapsing remitting multiple sclerosis.